retatrutide weight loss trial retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Phase 3 TRIUMPH-4 Results:

Avoid Over-Dilution: Adding too much water (e.g., 10 mL to a 2 mg vial) results in a dilute solution, requiring larger injection volumes that may be impractical or uncomfortable

patent expires in the early 2030s, with generic versions likely arriving 6-12 months after patent protection ends

404,405 Evinacumab, a monoclonal antibody targeting ANGPTL3, received FDA and European Medicines Agency (EMA) approval in 2021 for the treatment of HoFH

N., Egan, L., Mamotte, C., Stokes, R., Gunton, J

10.1056/NEJM199305203282004

These medications have been associated with an increase in gallbladder disease, pancreatitis, and delayed gastric emptying that may contribute to nausea, vomiting, and postponement of absorption of other medications